Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radafaxine in Major Depressive Disorder
NCT00057226Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2003
- Primary completion
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Radafaxine with Placebo (2 arms). Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Mar 2003; status: completed.
02
Drugs
radafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00057226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057226.